Fujirebio Diagnostics, Inc. Stacey Dolan Manager, Regulatory Affairs 201 Great Valley Parkway Malvern, Pennsylvania 19355

Re: K172713 Trade/Device Name: Lumipulse G B‚Ä¢R‚Ä¢A‚Ä¢H‚Ä¢M‚Ä¢S PCT Immunoreaction Cartridges, Lumipulse G B‚Ä¢R‚Ä¢A‚Ä¢H‚Ä¢M‚Ä¢S PCT Calibrators set Regulation Number: 21 CFR 866.3215 Regulation Name: Device to detect and measure non-microbial analyte(s) in human clinical specimens to aid in assessment of patients with suspected sepsis Regulatory Class: Class II Product Code: PRI, PMT, NTM Dated: September 7, 2017 Received: September 8, 2017

Dear Stacey Dolan:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part

801 and Part 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice   
(https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn   
(http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,y

'PSKristian M. Roth -S

Uwe Scherf, Ph.D.   
Director   
Division of Microbiology Devices   
Office of In Vitro Diagnostics   
and Radiological Health   
Center for Devices and Radiological Health

Enclosure

Device Name Lumipulse G B‚Ä¢R‚Ä¢A‚Ä¢H‚Ä¢M‚Ä¢S PCT Immunoreaction Cartridges Lumipulse G B‚Ä¢R‚Ä¢A‚Ä¢H‚Ä¢M‚Ä¢S PCT Calibrators set

Indications for Use (Describe) Lumipulse G B‚Ä¢R‚Ä¢A‚Ä¢H‚Ä¢M‚Ä¢S PCT Immunoreaction Cartridges:

The Lumipulse G B‚Ä¢R‚Ä¢A‚Ä¢H‚Ä¢M‚Ä¢S PCT is a Chemiluminescent Enzyme Immunoassay (CLEIA) for the quantitative determination of PCT (procalcitonin) in human serum and plasma (sodium heparin, lithium heparin, sodium citrate or dipotassium EDTA) on the LUMIPULSE G System.

Used in conjunction with other laboratory findings and clinical assessments, Lumipulse G B‚Ä¢R‚Ä¢A‚Ä¢H‚Ä¢M‚Ä¢S PCT is intended for use as an:

‚Ä¢ Aid in the risk assessment of critically ill patients on their first day of intensive care unit (ICU) admission for progression to severe sepsis and septic shock.

‚Ä¢ Aid in assessing the cumulative 28-day risk of all-cause mortality for patients diagnosed with severe sepsis or septic shock in the ICU or when obtained in the emergency department or other medical wards prior to ICU admission, using a change in PCT level over time.

‚Ä¢ Aid in decision making on antibiotic therapy for patients with suspected or confirmed lower respiratory tract infections (LRTI) ‚Äì defined as community acquired pneumonia (CAP), acute bronchitis, and acute exacerbation of chronic obstructive pulmonary disease (AECOPD) ‚Äì in an inpatient setting or an emergency department.

‚Ä¢ Aid in decision making on antibiotic discontinuation for patients with suspected or confirmed sepsis.

Lumipulse G B‚àôR‚àôA‚àôH‚àôM‚àôS PCT Calibrators set

Lumipulse G B‚àôR‚àôA‚àôH‚àôM‚àôS PCT Calibrators set is for in vitro diagnostic use in the calibration of Lumipulse G B‚àôR‚àôA‚àôH‚àôM‚àôS PCT on the LUMIPULSE G System.

# CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

# \*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.\*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

‚ÄúAn agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number.‚Äù

# Section 5

# 510(k) SUMMARY

Lumipulse¬Æ G PCT

Date: December 6, 2017

A. 510(k) Number: K172713

B. Purpose of Submission: New device

C. Measurand: Procalcitonin

D. Type of Test: Quantitative assay, automated chemiluminescent enzyme immunoassay (CLEIA)

# E. Applicant:

Submitter:

Fujirebio Diagnostics, Inc. 201 Great Valley Parkway Malvern, PA 19355

# Contact Person:

Stacey Dolan Manager, Regulatory Affairs Phone: (610) 240-3843 Fax: (610) 240-3803 Email: dolans@fdi.com

F. Proprietary and Established Names: Lumipulse¬Æ G B‚Ä¢R‚Ä¢A‚Ä¢H‚Ä¢M‚Ä¢S PCT

G. Regulatory Information: 1. Regulation section: 21 CFR $\ S$ 866.3215

2. Classification: Class II

3. Product codes: PRI, NTM, PMT

4. Panel: 83, Microbiology

# H. Intended Use:

1. Intended Use:

# Lumipulse G B‚Ä¢R‚Ä¢A‚Ä¢H‚Ä¢M‚Ä¢S PCT Immunoreaction Cartridges

The Lumipulse G B‚Ä¢R‚Ä¢A‚Ä¢H‚Ä¢M‚Ä¢S PCT is a Chemiluminescent Enzyme Immunoassay (CLEIA) for the quantitative determination of PCT (procalcitonin) in human serum and plasma (sodium heparin, lithium heparin, sodium citrate or dipotassium EDTA) on the LUMIPULSE G System.

Used in conjunction with other laboratory findings and clinical assessments, Lumipulse G B‚Ä¢R‚Ä¢A‚Ä¢H‚Ä¢M‚Ä¢S PCT is intended for use as an:

Aid in the risk assessment of critically ill patients on their first day of intensive care unit (ICU) admission for progression to severe sepsis and septic shock.   
Aid in assessing the cumulative 28-day risk of all-cause mortality for patients diagnosed with severe sepsis or septic shock in the ICU or when obtained in the   
emergency department or other medical wards prior to ICU admission, using a change   
in PCT level over time.   
Aid in decision making on antibiotic therapy for patients with suspected or confirmed   
lower respiratory tract infections (LRTI) ‚Äì defined as community acquired pneumonia   
(CAP), acute bronchitis, and acute exacerbation of chronic obstructive pulmonary   
disease (AECOPD) ‚Äì in an inpatient setting or an emergency department.   
Aid in decision making on antibiotic discontinuation for patients with suspected or confirmed sepsis.

# Lumipulse G B‚Ä¢R‚Ä¢A‚Ä¢H‚Ä¢M‚Ä¢S PCT Calibrators Set

Lumipulse G B‚Ä¢R‚Ä¢A‚Ä¢H‚Ä¢M‚Ä¢S PCT Calibrators set are for in vitro diagnostic use in the calibration of LUMIPULSE G B‚Ä¢R‚Ä¢A‚Ä¢H‚Ä¢M‚Ä¢S PCT on the LUMIPULSE G System.

2. Indications for use: Same as Intended Use.

3. Special conditions for use statement(s): Prescription use only.

4. Special instrument requirements: LUMIPULSE G1200 System

# I. Device Description:

Lumipulse G B‚Ä¢R‚Ä¢A‚Ä¢H‚Ä¢M‚Ä¢S PCT is an assay system, including a set of immunoassay reagents, for the quantitative measurement of PCT in specimens based on CLEIA technology by a two-step sandwich immunoassay method on the LUMIPULSE G1200 System.

Lumipulse G B‚Ä¢R‚Ä¢A‚Ä¢H‚Ä¢M‚Ä¢S PCT Immunoreaction Cartridges: IRC 235058. The Lumipulse G B‚Ä¢R‚Ä¢A‚Ä¢H‚Ä¢M‚Ä¢S PCT Immunoreaction Cartridges consists of $3 \times 1 4$ tests. Each kit contains the following:

1.) Antibody-Coated Particle Solution   
(Liquid when used, 250 ŒºL/Immunoreaction Cartridge) Contains $1 5 0 ~ \mu \ g / \mu \mathrm { u } L$ anti-PCT monoclonal antibody (mouse) and anti-calcitonin monoclonal antibody (mouse) coated particles, protein stabilizers (bovine and mouse) and chemical stabilizers in 0.15 M sodium chloride/Tris buffer. This solution contains gelatin and turns into gel at $1 5 ^ { \circ } \mathsf { C }$ or lower. Preservative: sodium azide. 2.) Enzyme-Labeled Antibody Solution   
(Liquid, 350 ŒºL/Immunoreaction Cartridge)   
Contains $0 . 2 5 \mu { \sf g } / { \sf m L }$ alkaline phosphatase (ALP: calf)-labeled anti-katacalcin monoclonal antibody (mouse), protein stabilizers (bovine, calf and mouse) and chemical stabilizers in 0.1 M sodium chloride/MES buffer. Preservative: sodium azide. Lumipulse G B‚Ä¢R‚Ä¢A‚Ä¢H‚Ä¢M‚Ä¢S PCT Calibrators set CAL SET 234150, Lyophilized, 2 √ó 2 Concentrations   
Each calibrator kit contains one bottle each of Calibrators 1 ‚Äì 2, and Reconstituting Solution. The calibrator kit is packaged separately. CAL 1 0 ng/mL PCT calibrator $( 2 \times 0 . 5 \ : \mathrm { m L } / \mathrm { v i a l } )$   
CAL 2 100 ng/mL PCT calibrator $( 2 \times 0 . 5 \ : \mathrm { m L } / \mathrm { v i a l } )$   
Contains procalcitonin in 0.15 M sodium chloride in Tris buffer with protein stabilizer (bovine). Preservative: ProClin 300.

RS Reconstituting Solution: Liquid, $1 \times 1 0 ~ \mathrm { m L }$

Preservative: sodium azide.

These calibrators are lyophilized and have to be prepared by adding exactly $0 . 5 ~ \mathsf { m L }$ of Reconstituting Solution to each lyophilized calibrator.

J. Substantial Equivalence:

1. Predicate device name(s): B‚Ä¢R‚Ä¢A‚Ä¢H‚Ä¢M‚Ä¢S PCT sensitive KRYPTOR¬Æ

2. Predicate 510(k) number(s): k171338

3. Comparison with predicate:

Comparison between the Lumipulse¬Æ G B‚Ä¢R‚Ä¢A‚Ä¢H‚Ä¢M‚Ä¢S PCT and B‚Ä¢R‚Ä¢A‚Ä¢H‚Ä¢M‚Ä¢S PCT sensitive KRYPTOR¬Æ   

<table><tr><td colspan="3" rowspan="1">Similarities and Differences</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Lumipulse¬Æ GB¬∑R¬∑A¬∑H‚Ä¢M‚Ä¢S PCT (ProposedDevice)</td><td colspan="1" rowspan="1">B¬∑R¬∑A¬∑H‚Ä¢M¬∑S PCT sensitiveKRYPTOR¬Æ(Predicate Device)K171338</td></tr><tr><td colspan="1" rowspan="1">Device Type</td><td colspan="1" rowspan="1">In vitro diagnostic</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Classification</td><td colspan="1" rowspan="1">Class II</td><td colspan="1" rowspan="1">Same</td></tr><tr><td></td><td>Lumipulse¬Æ G B¬∑R¬∑A¬∑H¬∑M¬∑S PCT (Proposed Device</td><td>B¬∑R‚Ä¢A¬∑H¬∑M¬∑S PCT sensitive KRYPTOR (Predicate Device) K171338</td></tr><tr><td>Analyte</td><td>Procalcitonin 21CFR ¬ß 866.3215; Device to</td><td>Same</td></tr><tr><td>Regulation Number</td><td>detect and measure non- microbial analyte(s) in human clinical specimens to aid in assessment of patients with</td><td>Same</td></tr><tr><td>Product Usage</td><td>suspected sepsis Clinical and Hospital laboratories</td><td>Same</td></tr><tr><td>Principle of Operation</td><td>Automated Quantitative Chemiluminscent Enzyme Immunoassay (CLEIA)</td><td>Time-Resolved Amplified Cryptate Emission (TRACE)</td></tr><tr><td>Specimen Collection Method</td><td>Routine Phlebotomy Techniques The Lumipulse G B¬∑R¬∑A¬∑H‚Ä¢M¬∑S</td><td>Same The B¬∑R¬∑A¬∑H¬∑M.S</td></tr><tr><td rowspan="8">Intended Use</td><td>PCT is a Chemiluminescent Enzyme Immunoassay (CLEIA) for the quantitative determination of PCT (procalcitonin) in human serum and plasma ‚àí (sodium heparin, lithium heparin, sodium citrate or dipotassium EDTA) on the LUMIPULSE G System.</td><td>PCT sensitive KRYPTOR¬Æ is an immunofluorescent assay using Time- Resolved Amplified Cryptate Emission</td></tr><tr><td>Used in conjunction with other laboratory findings and clinical assessments, Lumipulse G B¬∑R¬∑A‚Ä¢H‚Ä¢M¬∑S PCT is intended for</td><td>(TRACE) technology to determine the concentration of PCT (procalcitonin) in human serum and EDTA or heparin</td></tr><tr><td>use as an: Aid in the risk assessment of critically ill patients on</td><td>plasma. The B¬∑R¬∑A¬∑H¬∑M.S</td></tr><tr><td>their first day of intensive care unit (ICU) admission</td><td>PCT sensitive KRYPTOR¬Æ is intended to be</td></tr><tr><td>for progression to severe sepsis and septic shock.</td><td>performed on the B¬∑RA¬∑H¬∑M.S KRYPTOR¬Æ analyzer</td></tr><tr><td>Aid in assessing the cumulative 28-day risk of</td><td>family.</td></tr><tr><td>all-cause mortality with</td><td>Used in conjunction</td></tr><tr><td>patients diagnosed</td><td>for with other laboratory findings and clinical</td></tr></table>

<table><tr><td colspan="5" rowspan="1">Similarities and Differences</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="3" rowspan="1">Lumipulse¬Æ GB‚Ä¢R¬∑A¬∑H‚Ä¢M‚Ä¢S PCT (ProposedDevice)</td><td colspan="1" rowspan="1">B¬∑R¬∑A¬∑H¬∑M¬∑S PCT sensitiveKRYPTOR(Predicate Device)K171338</td></tr><tr><td colspan="1" rowspan="6"></td><td colspan="3" rowspan="6">department   or   othermedical wards prior to ICUadmission, using a changein PCT level over time.Aid in decision making onantibiotic  therapy‚àíforpatients with suspected orconfirmed             lowerrespiratory tract infections(LRTI)    defined ascommunity       acquiredpneumonia (CAP), acutebronchitis,   and  acuteexacerbationofchronicobstructive    pulmonarydisease (AECOPD) - in aninpatientt settingor anemergency department.Aid in decision making onantibiotic discontinuationfor patients with suspectedor confirmed sepsis.</td><td colspan="1" rowspan="6">is intended for use asfollows:to aid in the riskassessment ofcritically ill patientson their first day ofICU admission forprogression to severesepsis and septicshock,to determine thechange in PCT levelover time as an aid inassessing the cumulative28-dayrisk of all-causemortality for patientsdiagnosed withsevere sepsis orseptic shock in theICU or whenobtained in theemergencydepartment or othermedical wards priorto ICU admission,to aid in decisionmaking on antibiotictherapy, forinpatients or patientsin the emergencydepartment withsuspected orconfirmed lowerrespiratory tractinfections (LRTI) -defined ascommunity-acquiredpneumonia (CAP),acute bronchitis, andacute exacerbationof chronic</td></tr><tr><td colspan="1" rowspan="1"></td></tr><tr><td colspan="2" rowspan="1"></td></tr><tr><td colspan="2" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">brorc</td></tr><tr><td colspan="3" rowspan="1">Similarities and Differences</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Lumipulse¬Æ GB¬∑R‚Ä¢A¬∑H‚Ä¢M‚Ä¢S PCT (ProposedDevice)</td><td colspan="1" rowspan="1">B¬∑R‚Ä¢A¬∑H¬∑M¬∑S PCT sensitiveKRYPTOR¬Æ(Predicate Device)K171338</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">obstructivepulmonary disease(AECOPD),to aid in decisionmaking on antibioticdiscontinuation forpatients withsuspected orconfirmed sepsis.</td></tr><tr><td colspan="1" rowspan="1">Instrument System</td><td colspan="1" rowspan="1">LUMIPULSE G System</td><td colspan="1" rowspan="1">The BRAHMS KRYPTORanalyzer</td></tr><tr><td colspan="1" rowspan="1">Assay Type</td><td colspan="1" rowspan="1">Two-step sandwichimmunoassay based onchemiluminescenttechnology</td><td colspan="1" rowspan="1">Immunofluorescent assay</td></tr><tr><td colspan="1" rowspan="1">Type of Specimen</td><td colspan="1" rowspan="1">Human serum and plasma(sodium heparin, lithium heparin,sodium citrate or dipotassiumEDTA)</td><td colspan="1" rowspan="1">Human serum and plasma(EDTA, heparin)</td></tr><tr><td colspan="1" rowspan="1">Assay Range</td><td colspan="1" rowspan="1">0.020 - 100 ng/mL</td><td colspan="1" rowspan="1">0.02-5000ng/mL</td></tr><tr><td colspan="1" rowspan="1">Sample Volume</td><td colspan="1" rowspan="1">60 Œºl</td><td colspan="1" rowspan="1">50Œºl</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

CLSI EP5-A3 - Evaluation of Precision of Quantitative Measurement Procedures; Approved   
Guideline - Third Edition   
CLSI EP7-A2 - Interference Testing in Clinical Chemistry; Approved Guideline-Second   
Edition   
CLSI EP28-A3c - Defining, Establishing, and Verifying Reference Intervals in the Clinical   
Laboratory; Approved Guideline-Third Edition   
CLSI EP17-A2 - Evaluation of Detection Capability for Clinical Laboratory Measurement   
Procedures; Approved Guideline Second Edition   
CLSI EP6-A - Evaluation of the Linearity of Quantitative Measurement Procedures: A   
Statistical Approach; Approved Guideline   
CLSI EP9-A3 ‚Äì Measurement Procedure Comparison and Bias Estimation Using Patient   
Samples; approved Guideline ‚Äì Third Edition   
CLSI EP25-A ‚Äì Evaluation of Stability of In Vitro Diagnostic Reagents: Approved Guideline   
Guidance on Informed Consent for In Vitro Diagnostic Device Studies Using Leftover   
Human Specimens that are Not Individually Identifiable - Guidance for Sponsors,   
Institutional Review Boards, Clinical Investigators and FDA Staff   
Test Principle: Guidance for Industry and Food and Drug Administration Staff - eCopy   
Program for Medical Device Submissions (December 31, 2012)

Guidance for Industry and Food and Drug Administration Staff - Refuse to Accept Policy for 510(k)s (August 4, 2015)

# L. Test Principle:

Lumipulse G B‚Ä¢R‚Ä¢A‚Ä¢H‚Ä¢M‚Ä¢S PCT is an assay system, including a set of immunoassay reagents, for the quantitative measurement of PCT in specimens based on CLEIA technology by a twostep sandwich immunoassay method on the LUMIPULSE G1200 System.

PCT in specimens specifically binds to anti-PCT monoclonal antibody (mouse) and anti-calcitonin monoclonal antibody (mouse) on the particles, and antigen-antibody immunocomplexes are formed. The particles are washed and rinsed to remove unbound materials. Alkaline phosphatase (ALP: calf)-labeled anti-katacalcin monoclonal antibody (mouse) specifically binds to PCT of the immunocomplexes on the particles, and additional immunocomplexes are formed. The particles are washed and rinsed to remove unbound materials. Substrate Solution is added and mixed with the particles. AMPPD contained in the Substrate Solution is dephosphorylated by the catalysis of ALP indirectly conjugated to particles. Luminescence (at a maximum wavelength of 477 nm) is generated by the cleavage reaction of dephosphorylated AMPPD. The luminescent signal reflects the amount of PCT.

# M. Performance Characteristics

Data were generated using the LUMIPULSE G1200 System.

1. Analytical performance:

a. Precision/Reproducibility:

20 Day

The results of the 20-day precision calculations for Lumipulse G B‚Ä¢R‚Ä¢A‚Ä¢H‚Ä¢M‚Ä¢S PCT performed at FDI are shown below:

Lot A ICs/Lot A Calibrators for Control Levels 1-3 and Panels 1-6   
Lot D ICs/Lot D Calibrators for Panels 7 and 8

The analyses determined the total precision for the Lumipulse G B‚Ä¢R‚Ä¢A‚Ä¢H‚Ä¢M‚Ä¢S PCT assay to be $\leq 4 . 7 \%$ . The total precision of the Lumipulse G B‚Ä¢R‚Ä¢A‚Ä¢H‚Ä¢M‚Ä¢S PCT for the eight (8) panels ranged from $1 . 8 \%$ to $3 . 1 \%$ . The total precision of the Lumipulse $\pmb { G }$ B‚Ä¢R‚Ä¢A‚Ä¢H‚Ä¢M‚Ä¢S PCT for the three (3) controls ranged from $3 . 3 \%$ to $4 . 7 \%$ . The precision of all controls and panels for the 20-day Precision Study met the acceptance criteria of a $\mathrm { C V } \leq 1 0 \%$ .

Summary for FDI 20-day Precision $[ n = 8 0$ for each sample) for Lot A (Controls and Panels 1-6) and Lot D (Panels 7 and 8)   

<table><tr><td rowspan=1 colspan=2></td><td rowspan=1 colspan=2>Within-Run(Repeatability)</td><td rowspan=1 colspan=2>Between Run</td><td rowspan=1 colspan=2>Between-Day</td><td rowspan=1 colspan=2>Within-Laboratory(Total)</td></tr><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Mean(ng/mL)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Control Level 1</td><td rowspan=1 colspan=1>0.662</td><td rowspan=1 colspan=1>0.010</td><td rowspan=1 colspan=1>1.6%</td><td rowspan=1 colspan=1>0.026</td><td rowspan=1 colspan=1>3.9%</td><td rowspan=1 colspan=1>0.014</td><td rowspan=1 colspan=1>2.1%</td><td rowspan=1 colspan=1>0.031</td><td rowspan=1 colspan=1>4.7%</td></tr><tr><td rowspan=1 colspan=1>Control Level 2</td><td rowspan=1 colspan=1>3.911</td><td rowspan=1 colspan=1>0.045</td><td rowspan=1 colspan=1>1.2%</td><td rowspan=1 colspan=1>0.129</td><td rowspan=1 colspan=1>3.3%</td><td rowspan=1 colspan=1>0.026</td><td rowspan=1 colspan=1>0.7%</td><td rowspan=1 colspan=1>0.139</td><td rowspan=1 colspan=1>3.6%</td></tr><tr><td rowspan=1 colspan=1>Control Level 3</td><td rowspan=1 colspan=1>14.978</td><td rowspan=1 colspan=1>0.163</td><td rowspan=1 colspan=1>1.1%</td><td rowspan=1 colspan=1>0.393</td><td rowspan=1 colspan=1>2.6%</td><td rowspan=1 colspan=1>0.245</td><td rowspan=1 colspan=1>1.6%</td><td rowspan=1 colspan=1>0.490</td><td rowspan=1 colspan=1>3.3%</td></tr><tr><td rowspan=1 colspan=1>Panel 1</td><td rowspan=1 colspan=1>0.300</td><td rowspan=1 colspan=1>0.005</td><td rowspan=1 colspan=1>1.6%</td><td rowspan=1 colspan=1>0.004</td><td rowspan=1 colspan=1>1.5%</td><td rowspan=1 colspan=1>0.003</td><td rowspan=1 colspan=1>1.0%</td><td rowspan=1 colspan=1>0.007</td><td rowspan=1 colspan=1>2.4%</td></tr><tr><td rowspan=1 colspan=1>Panel 2</td><td rowspan=1 colspan=1>2.219</td><td rowspan=1 colspan=1>0.032</td><td rowspan=1 colspan=1>1.5%</td><td rowspan=1 colspan=1>0.016</td><td rowspan=1 colspan=1>0.7%</td><td rowspan=1 colspan=1>0.027</td><td rowspan=1 colspan=1>1.2%</td><td rowspan=1 colspan=1>0.045</td><td rowspan=1 colspan=1>2.0%</td></tr><tr><td rowspan=1 colspan=1>Panel 3</td><td rowspan=1 colspan=1>12.323</td><td rowspan=1 colspan=1>0.129</td><td rowspan=1 colspan=1>1.0%</td><td rowspan=1 colspan=1>0.144</td><td rowspan=1 colspan=1>1.2%</td><td rowspan=1 colspan=1>0.098</td><td rowspan=1 colspan=1>0.8%</td><td rowspan=1 colspan=1>0.217</td><td rowspan=1 colspan=1>1.8%</td></tr><tr><td rowspan=1 colspan=1>Panel 4</td><td rowspan=1 colspan=1>36.217</td><td rowspan=1 colspan=1>0.379</td><td rowspan=1 colspan=1>1.0%</td><td rowspan=1 colspan=1>0.308</td><td rowspan=1 colspan=1>0.8%</td><td rowspan=1 colspan=1>0.445</td><td rowspan=1 colspan=1>1.2%</td><td rowspan=1 colspan=1>0.661</td><td rowspan=1 colspan=1>1.8%</td></tr><tr><td rowspan=1 colspan=1>Panel 5</td><td rowspan=1 colspan=1>54.132</td><td rowspan=1 colspan=1>0.596</td><td rowspan=1 colspan=1>1.1%</td><td rowspan=1 colspan=1>0.529</td><td rowspan=1 colspan=1>1.0%</td><td rowspan=1 colspan=1>0.642</td><td rowspan=1 colspan=1>1.2%</td><td rowspan=1 colspan=1>1.024</td><td rowspan=1 colspan=1>1.9%</td></tr><tr><td rowspan=1 colspan=1>Panel 6</td><td rowspan=1 colspan=1>80.361</td><td rowspan=1 colspan=1>1.265</td><td rowspan=1 colspan=1>1.6%</td><td rowspan=1 colspan=1>0.879</td><td rowspan=1 colspan=1>1.1%</td><td rowspan=1 colspan=1>0.632</td><td rowspan=1 colspan=1>0.8%</td><td rowspan=1 colspan=1>1.666</td><td rowspan=1 colspan=1>2.1%</td></tr><tr><td rowspan=1 colspan=1>Panel 7</td><td rowspan=1 colspan=1>0.112</td><td rowspan=1 colspan=1>0.002</td><td rowspan=1 colspan=1>2.0%</td><td rowspan=1 colspan=1>0.002</td><td rowspan=1 colspan=1>2.2%</td><td rowspan=1 colspan=1>0.001</td><td rowspan=1 colspan=1>1.1%</td><td rowspan=1 colspan=1>0.004</td><td rowspan=1 colspan=1>3.1%</td></tr><tr><td rowspan=1 colspan=1>Panel 8</td><td rowspan=1 colspan=1>0.534</td><td rowspan=1 colspan=1>0.010</td><td rowspan=1 colspan=1>1.9%</td><td rowspan=1 colspan=1>0.008</td><td rowspan=1 colspan=1>1.5%</td><td rowspan=1 colspan=1>0.003</td><td rowspan=1 colspan=1>0.6%</td><td rowspan=1 colspan=1>0.013</td><td rowspan=1 colspan=1>2.5%</td></tr></table>

# Lot-To-Lot Reproducibility for Combined Data

The precision analyses for the combined lot-to-lot analysis for Lots A, B and C determined the total precision for Lumipulse $\pmb { G }$ PCT to be $\leq 5 . 3 \%$ in this study. The total precision for Lumipulse G B‚Ä¢R‚Ä¢A‚Ä¢H‚Ä¢M‚Ä¢S PCT to be $\leq 3 . 0 \%$ for the six (6) panels. The total precision for Lumipulse G PCT to be $\leq 5 . 3 \%$ for the three (3) controls. The total precision of Lumipulse $\pmb { G }$ B‚Ä¢R‚Ä¢A‚Ä¢H‚Ä¢M‚Ä¢S PCT ranged from $1 . 8 \%$ to $5 . 3 \%$ . The between-lot precision for Lumipulse G B‚Ä¢R‚Ä¢A‚Ä¢H‚Ä¢M‚Ä¢S PCT was $\leq 6 . 5 \%$ .

The precision of controls and panels for the lot-to-lot reproducibility met the targeted acceptance criteria of a $\mathrm { C V } \leq 1 0 \%$ .

Summary of the Lot-to-Lot Reproducibility for the Combined Data for Lots A, B and C ( $\bf { n } = 1 2 0$ for each sample)   

<table><tr><td rowspan=1 colspan=2></td><td rowspan=1 colspan=2>BetweenLots</td><td rowspan=1 colspan=2>BetweenDay</td><td rowspan=1 colspan=2>BetweenRun</td><td rowspan=1 colspan=2>Within Runs(Repeatability)</td><td rowspan=1 colspan=2>Within-Laboratory(Total)</td></tr><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Mean(ng/L)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Control Level1</td><td rowspan=1 colspan=1>0.634</td><td rowspan=1 colspan=1>0.030</td><td rowspan=1 colspan=1>4.7%</td><td rowspan=1 colspan=1>0.013</td><td rowspan=1 colspan=1>2.0%</td><td rowspan=1 colspan=1>0.030</td><td rowspan=1 colspan=1>4.7%</td><td rowspan=1 colspan=1>0.009</td><td rowspan=1 colspan=1>1.4%</td><td rowspan=1 colspan=1>0.033</td><td rowspan=1 colspan=1>5.3%</td></tr><tr><td rowspan=1 colspan=1>Control Level2</td><td rowspan=1 colspan=1>3.816</td><td rowspan=1 colspan=1>0.137</td><td rowspan=1 colspan=1>3.6%</td><td rowspan=1 colspan=1>0.016</td><td rowspan=1 colspan=1>0.4%</td><td rowspan=1 colspan=1>0.127</td><td rowspan=1 colspan=1>3.3%</td><td rowspan=1 colspan=1>0.055</td><td rowspan=1 colspan=1>1.4%</td><td rowspan=1 colspan=1>0.139</td><td rowspan=1 colspan=1>3.7%</td></tr><tr><td rowspan=1 colspan=1>Control Level3</td><td rowspan=1 colspan=1>14.875</td><td rowspan=1 colspan=1>0.313</td><td rowspan=1 colspan=1>2.1%</td><td rowspan=1 colspan=1>0.141</td><td rowspan=1 colspan=1>0.9%</td><td rowspan=1 colspan=1>0.434</td><td rowspan=1 colspan=1>2.9%</td><td rowspan=1 colspan=1>0.164</td><td rowspan=1 colspan=1>1.1%</td><td rowspan=1 colspan=1>0.487</td><td rowspan=1 colspan=1>3.3%</td></tr><tr><td rowspan=1 colspan=1>Panel 1</td><td rowspan=1 colspan=1>0.290</td><td rowspan=1 colspan=1>0.012</td><td rowspan=1 colspan=1>4.3%</td><td rowspan=1 colspan=1>0.004</td><td rowspan=1 colspan=1>1.3%</td><td rowspan=1 colspan=1>0.006</td><td rowspan=1 colspan=1>2.0%</td><td rowspan=1 colspan=1>0.005</td><td rowspan=1 colspan=1>1.8%</td><td rowspan=1 colspan=1>0.009</td><td rowspan=1 colspan=1>3.0%</td></tr><tr><td rowspan=1 colspan=1>Panel 2</td><td rowspan=1 colspan=1>2.163</td><td rowspan=1 colspan=1>0.075</td><td rowspan=1 colspan=1>3.4%</td><td rowspan=1 colspan=1>0.021</td><td rowspan=1 colspan=1>1.0%</td><td rowspan=1 colspan=1>0.038</td><td rowspan=1 colspan=1>1.8%</td><td rowspan=1 colspan=1>0.026</td><td rowspan=1 colspan=1>1.2%</td><td rowspan=1 colspan=1>0.048</td><td rowspan=1 colspan=1>2.2%</td></tr><tr><td rowspan=1 colspan=1>Panel 3</td><td rowspan=1 colspan=1>12.332</td><td rowspan=1 colspan=1>0.320</td><td rowspan=1 colspan=1>2.6%</td><td rowspan=1 colspan=1>0.221</td><td rowspan=1 colspan=1>1.8%</td><td rowspan=1 colspan=1>0.133</td><td rowspan=1 colspan=1>1.1%</td><td rowspan=1 colspan=1>0.122</td><td rowspan=1 colspan=1>1.0%</td><td rowspan=1 colspan=1>0.280</td><td rowspan=1 colspan=1>2.3%</td></tr><tr><td rowspan=1 colspan=1>Panel 4</td><td rowspan=1 colspan=1>38.147</td><td rowspan=1 colspan=1>2.280</td><td rowspan=1 colspan=1>6.0%</td><td rowspan=1 colspan=1>0.363</td><td rowspan=1 colspan=1>1.0%</td><td rowspan=1 colspan=1>0.467</td><td rowspan=1 colspan=1>1.2%</td><td rowspan=1 colspan=1>0.367</td><td rowspan=1 colspan=1>1.0%</td><td rowspan=1 colspan=1>0.701</td><td rowspan=1 colspan=1>1.8%</td></tr><tr><td rowspan=1 colspan=1>Panel 5</td><td rowspan=1 colspan=1>57.114</td><td rowspan=1 colspan=1>3.392</td><td rowspan=1 colspan=1>5.9%</td><td rowspan=1 colspan=1>0.856</td><td rowspan=1 colspan=1>1.5%</td><td rowspan=1 colspan=1>0.625</td><td rowspan=1 colspan=1>1.1%</td><td rowspan=1 colspan=1>0.674</td><td rowspan=1 colspan=1>1.2%</td><td rowspan=1 colspan=1>1.248</td><td rowspan=1 colspan=1>2.2%</td></tr><tr><td rowspan=1 colspan=1>Panel 6</td><td rowspan=1 colspan=1>86.233</td><td rowspan=1 colspan=1>5.585</td><td rowspan=1 colspan=1>6.5%</td><td rowspan=1 colspan=1>1.018</td><td rowspan=1 colspan=1>1.2%</td><td rowspan=1 colspan=1>1.138</td><td rowspan=1 colspan=1>1.3%</td><td rowspan=1 colspan=1>1.489</td><td rowspan=1 colspan=1>1.7%</td><td rowspan=1 colspan=1>2.141</td><td rowspan=1 colspan=1>2.5%</td></tr></table>

# Site to Site Reproducibility for Combined Data

The precision analyses for the combined site-to-site analysis for Lots A determined the total precision for Lumipulse G B‚Ä¢R‚Ä¢A‚Ä¢H‚Ä¢M‚Ä¢S PCT to be $\leq 4 . 9 \%$ in this study. The total precision for Lumipulse G B‚Ä¢R‚Ä¢A‚Ä¢H‚Ä¢M‚Ä¢S PCT to be $\leq 4 . 8 \%$ for the six (6) panels. The total precision for Lumipulse G PCT to be $\leq 4 . 9 \%$ for the three (3) controls. The total precision of Lumipulse G B‚Ä¢R‚Ä¢A‚Ä¢H‚Ä¢M‚Ä¢S PCT ranged from $2 . 9 \%$ to $4 . 9 \%$ . The betweensite precision for Lumipulse G B‚Ä¢R‚Ä¢A‚Ä¢H‚Ä¢M‚Ä¢S PCT was $\leq 4 . 7 \%$ .

The precision of the controls and panels for the site-to-site reproducibility met the targeted acceptance criteria of a $C V \leq 1 0 \%$ .

Summary of the Site-to-Site Reproducibility for the Combined Data for Lot A (n=120 for each panel)   

<table><tr><td rowspan=1 colspan=2></td><td rowspan=1 colspan=2>BetweenSites</td><td rowspan=1 colspan=2>BetweenDays</td><td rowspan=1 colspan=2>BetweenRuns</td><td rowspan=1 colspan=2>Within Runs(Repeatability)</td><td rowspan=1 colspan=2>Reproducibility(otal)</td></tr><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Mean(ng/mL)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Control Level 1</td><td rowspan=1 colspan=1>0.647</td><td rowspan=1 colspan=1>0.019</td><td rowspan=1 colspan=1>2.9%</td><td rowspan=1 colspan=1>0.023</td><td rowspan=1 colspan=1>3.5%</td><td rowspan=1 colspan=1>0.020</td><td rowspan=1 colspan=1>3.0%</td><td rowspan=1 colspan=1>0.012</td><td rowspan=1 colspan=1>1.8%</td><td rowspan=1 colspan=1>0.032</td><td rowspan=1 colspan=1>4.9%</td></tr><tr><td rowspan=1 colspan=1>Control Level 2</td><td rowspan=1 colspan=1>3.872</td><td rowspan=1 colspan=1>0.077</td><td rowspan=1 colspan=1>2.0%</td><td rowspan=1 colspan=1>0.109</td><td rowspan=1 colspan=1>2.8%</td><td rowspan=1 colspan=1>0.096</td><td rowspan=1 colspan=1>2.5%</td><td rowspan=1 colspan=1>0.054</td><td rowspan=1 colspan=1>1.4%</td><td rowspan=1 colspan=1>0.149</td><td rowspan=1 colspan=1>3.8%</td></tr><tr><td rowspan=1 colspan=1>Control Level 3</td><td rowspan=1 colspan=1>15.062</td><td rowspan=1 colspan=1>0.085</td><td rowspan=1 colspan=1>0.6%</td><td rowspan=1 colspan=1>0.337</td><td rowspan=1 colspan=1>2.2%</td><td rowspan=1 colspan=1>0.312</td><td rowspan=1 colspan=1>2.1%</td><td rowspan=1 colspan=1>0.166</td><td rowspan=1 colspan=1>1.1%</td><td rowspan=1 colspan=1>0.481</td><td rowspan=1 colspan=1>3.2%</td></tr><tr><td rowspan=1 colspan=1>Panel 1</td><td rowspan=1 colspan=1>0.291</td><td rowspan=1 colspan=1>0.008</td><td rowspan=1 colspan=1>2.8%</td><td rowspan=1 colspan=1>0.008</td><td rowspan=1 colspan=1>2.7%</td><td rowspan=1 colspan=1>0.010</td><td rowspan=1 colspan=1>3.6%</td><td rowspan=1 colspan=1>0.005</td><td rowspan=1 colspan=1>1.9%</td><td rowspan=1 colspan=1>0.014</td><td rowspan=1 colspan=1>4.8%</td></tr><tr><td rowspan=1 colspan=1>Panel 2</td><td rowspan=1 colspan=1>2.170</td><td rowspan=1 colspan=1>0.033</td><td rowspan=1 colspan=1>1.5%</td><td rowspan=1 colspan=1>0.049</td><td rowspan=1 colspan=1>2.3%</td><td rowspan=1 colspan=1>0.061</td><td rowspan=1 colspan=1>2.8%</td><td rowspan=1 colspan=1>0.032</td><td rowspan=1 colspan=1>1.5%</td><td rowspan=1 colspan=1>0.075</td><td rowspan=1 colspan=1>3.5%</td></tr><tr><td rowspan=1 colspan=1>Panel 3</td><td rowspan=1 colspan=1>12.297</td><td rowspan=1 colspan=1>0.375</td><td rowspan=1 colspan=1>3.0%</td><td rowspan=1 colspan=1>0.222</td><td rowspan=1 colspan=1>1.8%</td><td rowspan=1 colspan=1>0.417</td><td rowspan=1 colspan=1>3.4%</td><td rowspan=1 colspan=1>0.170</td><td rowspan=1 colspan=1>1.4%</td><td rowspan=1 colspan=1>0.485</td><td rowspan=1 colspan=1>3.9%</td></tr><tr><td rowspan=1 colspan=1>Panel 4</td><td rowspan=1 colspan=1>37.074</td><td rowspan=1 colspan=1>1.303</td><td rowspan=1 colspan=1>3.5%</td><td rowspan=1 colspan=1>0.586</td><td rowspan=1 colspan=1>1.6%</td><td rowspan=1 colspan=1>1.182</td><td rowspan=1 colspan=1>3.2%</td><td rowspan=1 colspan=1>0.361</td><td rowspan=1 colspan=1>1.0%</td><td rowspan=1 colspan=1>1.354</td><td rowspan=1 colspan=1>3.6%</td></tr><tr><td rowspan=1 colspan=1>Panel 5</td><td rowspan=1 colspan=1>55.428</td><td rowspan=1 colspan=1>2.043</td><td rowspan=1 colspan=1>3.7%</td><td rowspan=1 colspan=1>1.144</td><td rowspan=1 colspan=1>2.1%</td><td rowspan=1 colspan=1>1.385</td><td rowspan=1 colspan=1>2.5%</td><td rowspan=1 colspan=1>0.613</td><td rowspan=1 colspan=1>1.1%</td><td rowspan=1 colspan=1>1.846</td><td rowspan=1 colspan=1>3.3%</td></tr><tr><td rowspan=1 colspan=1>Panel 6</td><td rowspan=1 colspan=1>82.850</td><td rowspan=1 colspan=1>3.868</td><td rowspan=1 colspan=1>4.7%</td><td rowspan=1 colspan=1>1.006</td><td rowspan=1 colspan=1>1.2%</td><td rowspan=1 colspan=1>1.719</td><td rowspan=1 colspan=1>2.1%</td><td rowspan=1 colspan=1>1.285</td><td rowspan=1 colspan=1>1.6%</td><td rowspan=1 colspan=1>2.365</td><td rowspan=1 colspan=1>2.9%</td></tr></table>

# b. Linearity/assay reportable range:

Lumipulse G B‚Ä¢R‚Ä¢A‚Ä¢H‚Ä¢M‚Ä¢S PCT on the LUMIPULSE G1200 System demonstrated linearity in a study consistent with the guidelines in the CLSI Protocol EP6-A.9) High and low sample pools were created using patient serum samples that contained naturally expressed PCT. The linearity was found in the range of $0 . 0 1 0 ~ \mathrm { { n g / m L } }$ to $1 0 4 . 2 6 0 ~ \mathrm { { n g / m L } }$ . Lumipulse G B‚Ä¢R‚Ä¢A‚Ä¢H‚Ä¢M‚Ä¢S PCT correlated with expected concentrations according to the linear regression formula:

o y= 0.008734 + 0.856577; R-squared: 0.9979

High dose effect is a phenomenon whereby very high level specimens may read within the dynamic range of the assay. For Lumipulse G B‚Ä¢R‚Ä¢A‚Ä¢H‚Ä¢M‚Ä¢S PCT on the LUMIPULSE G1200 System, no high dose effect was observed for samples containing approximately $1 2 , 0 0 0 ~ \mathrm { { n g / m L } }$ of PCT.

c. Traceability, Stability, Expected values (controls, calibrators, or methods):

Calibration of the Lumipulse G B‚àôR‚àôA‚àôH‚àôM‚àôS PCT is traceable to in-house reference calibrators, whose values have been assigned to correlate to Thermo Fisher Scientific Inc.‚Äôs B‚àôR‚àôA‚àôH‚àôM‚àôS PCT sensitive Kryptor.

Cal Set Contains Cal 1 and Cal 2 $( 2 \times 0 . 5 \mathsf { m L } / \mathsf { v i a l } )$ and Reconstituting Solution $( 1 \times 1 0 \mathrm { m L } )$ . Preservative: ProClin 300. The calibrators are at the following concentrations:

<table><tr><td rowspan=1 colspan=1>Calibrator Level</td><td rowspan=1 colspan=1>PCT Concentration (ng/mL)</td></tr><tr><td rowspan=1 colspan=1>CAL 1</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>CAL 2</td><td rowspan=1 colspan=1>100</td></tr></table>

Master calibration data are recorded in a two-dimensional bar code on the Lumipulse G B‚Ä¢R‚Ä¢A‚Ä¢H‚Ä¢M‚Ä¢S PCT Immunoreaction Cartridge case. The calibration curve is created based on the recorded master calibration data and measured calibration data. The PCT concentration of a specimen is automatically calculated from the calibration curve. The result of the calculation is reported in ng/mL.

# Shelf life

The shelf life for Lumipulse G B‚Ä¢R‚Ä¢A‚Ä¢H‚Ä¢M‚Ä¢S PCT Immunoreaction Cartridges and the Lumipulse G B‚Ä¢R‚Ä¢A‚Ä¢H‚Ä¢M‚Ä¢S PCT Calibrators is 6 months at $2 { - } 1 0 ^ { \circ } \mathrm { C }$ .

# On board the LUMIPULSE G1200

The Lumipulse G B‚Ä¢R‚Ä¢A‚Ä¢H‚Ä¢M‚Ä¢S PCT Immunoreaction Cartridges are sealed unit dose stored at $2 { \cdot } 1 0 ^ { \circ } \mathsf C$ . To reduce risk for any misuse, the package insert states The Lumipulse G B‚Ä¢R‚Ä¢A‚Ä¢H‚Ä¢M‚Ä¢S PCT Cartridges can be stored on-board the LUMIPULSE G System for a maximum of 30 days.

The package insert recommends calibrator curve storage on the LUMIPULSE G1200 for a maximum of 30 days.

Transport Conditions   
Lumipulse G B‚Ä¢R‚Ä¢A‚Ä¢H‚Ä¢M‚Ä¢S PCT Immunoreaction Cartridges and the Lumipulse G B‚Ä¢R‚Ä¢A‚Ä¢H‚Ä¢M‚Ä¢S PCT Calibrators are shipped at $2 { \cdot } 1 0 ^ { \circ } \mathsf C$ .

Materials will be shipped to the end user using an insulated container and a predetermined configuration of gel (cold and/or frozen) packs to maintain the product for up to 72 hours when stored at ambient temperature.

# d. Detection limit:

The Limit of Blank (LoB), Limit of Detection (LoD), and Limit of Quantitation (LoQ) of Lumipulse G B‚Ä¢R‚Ä¢A‚Ä¢H‚Ä¢M‚Ä¢S PCT on the LUMIPULSE G1200 System is ‚â§0.0114 ng/mL.

1)LoB and LoD The LoB for Lumipulse G B‚Ä¢R‚Ä¢A‚Ä¢H‚Ä¢M‚Ä¢S PCT was 0.0095 ng/mL. The LoD for Lumipulse G PCT on the LUMIPULSE G1200 System was 0.0114 ng/mL, determined consistent with the guidelines in the CLSI Protocol EP17-A2, Seven low level specimens were tested over 3 days using two LUMIULSE G1200 Systems and two Lumipulse G PCT lots giving 120 determinations per panel.

The LoQ for Lumipulse G B‚Ä¢R‚Ä¢A‚Ä¢H‚Ä¢M‚Ä¢S PCT on the LUMIPULSE G1200 System was 0.0114 ng/mL, determined consistent with the guidelines in the CLSI Protocol EP17-A2.

A modeling analysis was conducted to evaluate the LOQ and for each lower cut-off (i.e., 0.10 ng/mL and 0.25 ng/mL). The Max $\%$ Total Error, $\%$ bias and $\% 0 \%$ were calculated, see below.

TE $\leq 1 1 . 4 \%$ at $0 . 2 5 ~ \mathrm { { n g / m L } }$ (with a $\%$ bias $\leq - 5 . 7 \%$ and a precision $C \mathsf { V } \leq 2 . 8 \%$ )

TE $\leq 1 4 . 1 \%$ at $0 . 1 0 ~ \mathrm { { n g / m L } }$ (with a $\%$ bias $\leq - 9 . 2 \%$ and a precision $C \mathsf { V } \leq 2 . 5 \%$ )

# e. Analytical specificity:

Lumipulse G B‚Ä¢R‚Ä¢A‚Ä¢H‚Ä¢M‚Ä¢S PCT on the LUMIPULSE G1200 System demonstrated an average interference of $\leq 1 0 \%$ (for each compound) in a study consistent with the guidelines in the CLSI Protocol EP7-A2 Human serum specimen pools with procalcitonin concentrations of approximately 0.25 and $2 . 0 \ : \mathrm { n g / m L }$ were supplemented with potentially interfering compounds. The following compounds were tested using Lumipulse G B‚Ä¢R‚Ä¢A‚Ä¢H‚Ä¢M‚Ä¢S PCT and found not to interfere with the assay.

<table><tr><td>Endogenous Interferences</td><td>Test Concentration</td></tr><tr><td>Free Bilirubin (unconjugated)</td><td>50 mg/dL</td></tr><tr><td>Conjugated Bilirubin</td><td>50 mg/dL</td></tr><tr><td>Hemoglobin</td><td>400 mg/dL</td></tr><tr><td>Total Protein (Human Serum Albumin)</td><td>12 g/dL</td></tr><tr><td>Triglycerides (Intralipid 20% Emulsion)</td><td>2500 mg/dL</td></tr><tr><td>Immunoglobulin G (IgG)</td><td>5 g/dL</td></tr><tr><td>Biotin</td><td>19.7 mg/dL</td></tr><tr><td>Human Anti-Mouse Antibodies (HAMA)</td><td>1,000 ng/mL</td></tr><tr><td>Rheumatoid Factor (RF)</td><td>1,000 IU/mL</td></tr></table>

<table><tr><td>Therapeutic Drug Interferences</td><td>Test Concentration (mg/dL)</td></tr><tr><td>Acetaminophen</td><td>20.01</td></tr><tr><td>AcetyIsalicylic Acid</td><td>65.22</td></tr><tr><td>1% Ethanol</td><td>789.00</td></tr><tr><td>Azithromycin</td><td>2.00</td></tr><tr><td>Caffeine</td><td>6.00</td></tr><tr><td>Celecoxib</td><td>24.00</td></tr><tr><td>Cetirizine HCI</td><td>0.55</td></tr><tr><td>Dextromethorphan</td><td>0.10</td></tr><tr><td>Dobutamine</td><td>1.13</td></tr><tr><td>Dopamine</td><td>13.00</td></tr><tr><td>Doxycycline</td><td>5.00</td></tr><tr><td>Epinephrine</td><td>0.18</td></tr><tr><td>Furosemide</td><td>2.00</td></tr><tr><td>Heparin</td><td>8000.00</td></tr><tr><td>Ibuprofen</td><td>50.03</td></tr><tr><td>Imipenem</td><td>118.00</td></tr><tr><td>Levofloxacin</td><td>2.93</td></tr></table>

<table><tr><td>Loratadine</td></tr><tr><td>Nicotine</td></tr><tr><td>0.10 Noradrenaline (norepinephrine) 0.20</td></tr><tr><td>Oxymetazoline HCI 0.09</td></tr><tr><td>Phenylephrine 6.00</td></tr><tr><td>Prednisolone 0.30</td></tr><tr><td>Salmeterol 0.006</td></tr><tr><td></td></tr><tr><td>Tiotropium 0.0022 Vancomycin 300.00</td></tr></table>

Lumipulse G B‚Ä¢R‚Ä¢A‚Ä¢H‚Ä¢M‚Ä¢S PCT on the LUMIPULSE G1200 System was evaluated for crossreactivity of the assay with other substances that are similar in structure to PCT in a study consistent with the guidelines in the CLSI Protocol EP7-A2. Human serum specimens with PCT concentrations of approximately 0.1, 0.25, 0.5, 2.0 and $8 0 ~ \mathrm { { n g / m L } }$ were supplemented with potentially cross-reacting compounds. The compounds were tested at the concentrations listed below and found to have the following percent cross-reactivity:

<table><tr><td rowspan=1 colspan=1>Cross-reactant</td><td rowspan=1 colspan=1>Test Concentration</td><td rowspan=1 colspan=1>Mean % Cross Reactivity</td></tr><tr><td rowspan=1 colspan=1>Human Calcitonin</td><td rowspan=1 colspan=1>10 ng/mL</td><td rowspan=1 colspan=1>-0.346%</td></tr><tr><td rowspan=1 colspan=1>Human Katacalcin</td><td rowspan=1 colspan=1>10 ng/mL</td><td rowspan=1 colspan=1>0.076%</td></tr><tr><td rowspan=1 colspan=1>Œ±-CGRP</td><td rowspan=1 colspan=1>10,000 ng/mL</td><td rowspan=1 colspan=1>0.002%</td></tr><tr><td rowspan=1 colspan=1>Œ≤-CGRP</td><td rowspan=1 colspan=1>10,000 ng/mL</td><td rowspan=1 colspan=1>0.001%</td></tr><tr><td rowspan=1 colspan=1>Salmon Calcitonin</td><td rowspan=1 colspan=1>13.2 Œºg/mL</td><td rowspan=1 colspan=1>-0.001%</td></tr><tr><td rowspan=1 colspan=1>Eel Calcitonin</td><td rowspan=1 colspan=1>7.5 ¬µg/mL</td><td rowspan=1 colspan=1>-0.001%</td></tr></table>

f. Assay cut-off: See Clinical Cutoff in 4 below.

2. Comparison studies:

a. Method Comparison

The Lumipulse G B‚Ä¢R‚Ä¢A‚Ä¢H‚Ä¢M‚Ä¢S PCT method comparison was performed on the LUMIPULSE G1200 System in a study consistent with the guidelines in CLSI Protocol EP09-A3.

The weighted Deming regression method was used to compare Lumipulse G B‚Ä¢R‚Ä¢A‚Ä¢H‚Ä¢M‚Ä¢S PCT to B‚Ä¢R‚Ä¢A‚Ä¢H‚Ä¢M‚Ä¢S PCT sensitive KRYPTOR. The lithium heparin specimens tested ranged from 0.054-58.156 ng/mL for Lumipulse G B‚Ä¢R‚Ä¢A‚Ä¢H‚Ä¢M‚Ä¢S PCT. The data are summarized in the following table.

<table><tr><td colspan="5">Lumipulse G B¬∑R¬∑A¬∑H¬∑M¬∑S PCT vs. B¬∑R¬∑A¬∑H¬∑M¬∑S PCT sensitive KRYPTOR</td></tr><tr><td>n</td><td>Correlation Coefficient (r)</td><td>Intercept (95% CI)</td><td>Slope (95% CI)</td><td>Mean Difference (ng/mL)</td></tr><tr><td>207</td><td>0.9535</td><td>-0.0044 (-0.0223 to</td><td>1.0199 (0.9633 to</td><td>0.185</td></tr></table>

# b. Matrix Comparison

The Lumipulse G B‚Ä¢R‚Ä¢A‚Ä¢H‚Ä¢M‚Ä¢S PCT matrix comparison study was performed to evaluate the difference across tube types (SST, K2EDTA, Lithium Heparin, Sodium Heparin, and Sodium Citrate) versus the means of the control samples (Red top serum) analyzed per CLSI guideline EP9-A3. The slope for each tube type when compared to the control had $9 5 \%$ confidence intervals that lay entirely within the range 0.9 to 1.1 and the correlation coefficients were $\geq 0 . 9$ .

3. Clinical studies:

a. Clinical sensitivity: Not applicable

b. Clinical specificity:   
Not applicable   
c. Other clinical supportive data (when a. and b. are not applicable):   
Not applicable

4. Clinical cut-off: See Expected Values below.

5. Expected values/Reference range:

In a population of 213 self-reported healthy individuals, the 95th percentile, upper reference range limit was calculated at 0.045 ng/mL.

It is recommended that each laboratory establish its own range, which may be unique to the population it serves depending upon geographical, patient, and environmental factors.

# N. Proposed Labeling

The labeling satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion

The results of these analytical (nonclinical) and clinical studies demonstrate that the Lumipulse G B‚Ä¢R‚Ä¢A‚Ä¢H‚Ä¢M‚Ä¢S PCT assay is substantially equivalent to the performance of the B‚Ä¢R‚Ä¢A‚Ä¢H‚Ä¢M‚Ä¢S PCT sensitive KRYPTOR.